A phase1 Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Ribociclib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis
- 14 Mar 2017 Status changed from active, no longer recruiting to completed.
- 09 Feb 2017 Planned End Date changed from 1 Dec 2016 to 15 Mar 2017.
- 09 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 15 Mar 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History